Aurobindo Pharma Share Price Rebounds 3% After Clarification on USFDA Inspection

Aurobindo Pharma share price (NSE: AUROPHARMA) gained about 3% in intraday trade, reaching nearly ₹1,195 despite overall market weakness. The stock rebounded around 6% from Wednesday’s low of ₹1,130 after the company issued a clarification regarding the inspection at its Unit VII facility. Earlier, the stock had fallen nearly 5% during Wednesday’s session.

Reason Behind Wednesday’s Decline

Media reports highlighted observations from the United States Food and Drug Administration inspection, including deficiencies in manufacturing and quality control. These reportedly involved falsified sample collection records, gaps in laboratory documentation, lack of continuous GMP training, weak computerised system controls, and environmental monitoring issues.

Company’s Clarification

Aurobindo stated that regulatory inspections by global authorities are routine and that any observations are addressed through established compliance procedures. The company has already informed stock exchanges about the inspection’s completion and will respond to the regulator within the required timeline. It added that no further material disclosures are currently necessary.

About Aurobindo Pharma

Aurobindo Pharma Limited is a multinational drug manufacturing company headquartered in HITEC City, Hyderabad, with its U.S. base located in East Windsor, New Jersey. The company produces generic medicines as well as active pharmaceutical ingredients (APIs).

Also Read: Best PSU Stocks in India in February 2026!

Conclusion

Aurobindo Pharma’s share recovery reflects investor confidence after regulatory concerns were clarified. While compliance costs and scrutiny may affect short-term performance, strong global growth drivers and margin expectations support a positive long-term outlook.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.